Medicine
Targeted Therapy for BRAF-Mutant Melanoma
Quick fact
About half of all melanomas carry a BRAF V600E mutation, and targeted therapies can shrink tumors in most patients within weeks—but resistance usually develops within a year if used alone.
Why this is interesting
Imagine a cancer that can be turned off like a light switch—but only for a while. What happens when the cancer learns to turn the light back on?